Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Updated Phase I study results of PHE885 in patients with R/R multiple myeloma

Nikhil Munshi • 9 Jun 2023
ASCO 2023
Multiple Myeloma CAR-T PHE885

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the features and advantages of PHE885, a CAR-T therapy manufactured in less than two days, which allows the product to preserve T-cell stemness. The Phase I study (NCT04318327) reported an overall response rate (ORR) of 98%.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nikhil Munshi

1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023
1:05
Alterations to the bone marrow microenvironment in patients with AL amyloidosis
Nikhil Munshi • 11 Dec 2023
2:42
Immunotherapeutic approaches to overcoming drug resistance in venetoclax-exposed patients with MM
Nikhil Munshi • 11 Dec 2023
2:32
Final results of CARTITUDE-1: cilta-cel in heavily pretreated patients with R/R multiple myeloma
Nikhil Munshi • 9 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals